Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination drug is a topical nasal preparation used primarily for the symptomatic relief of nasal congestion, allergic rhinitis, and sinusitis. It contains **naphazoline hydrochloride**, a sympathomimetic amine that acts as a potent vasoconstrictor by stimulating alpha-adrenergic receptors in the nasal mucosa, thereby reducing swelling and congestion. **Chlorpheniramine maleate** is a first-generation antihistamine that antagonizes H1 receptors, effectively reducing allergic symptoms such as sneezing, itching, and rhinorrhea. **Benzalkonium bromide** serves as both an antiseptic to reduce local bacterial presence and a preservative to maintain the stability of the solution. Together, these components provide rapid relief from upper respiratory allergies and inflammatory conditions of the nasal passages.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naphazoline hydrochloride + chlorpheniramine maleate + benzalkonium bromide.